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DOI 10.1016/j.ccr.2012.03.039SUMMARYRecent studies underscore the importance ofmyeloid cells in rendering distant organs hospitable for dissem-
inating tumor cells to colonize. However, what enables myeloid cells to have an apparently superior capacity
to colonize distant organs is unclear. Here, we show that S1PR1-STAT3 upregulation in tumor cells induces
factors that activate S1PR1-STAT3 in various cells in premetastatic sites, leading to premetastatic niche
formation. Targeting either S1PR1 or STAT3 in myeloid cells disrupts existing premetastatic niches.
S1PR1-STAT3 pathway enables myeloid cells to intravasate, prime the distant organ microenvironment
and mediate sustained proliferation and survival of their own and other stromal cells at future metastatic
sites. Analyzing tumor-free lymph nodes from cancer patients shows elevated myeloid infiltrates, STAT3
activity, and increased survival signal.INTRODUCTION
Several seminal studies have documented the importance of
myeloid cells in providing a sanctuary for tumor cells to adhere,
survive, and colonize secondary sites (Erler et al., 2009; Hirat-
suka et al., 2006; Kaplan et al., 2005; Kim et al., 2009; Kowanetz
et al., 2010; Psaila and Lyden, 2009). Although myeloid cells are
mobile and produce chemokines and other molecules in
response to the tumor environment thereby promoting cancer
progression (Biswas and Mantovani, 2010; Coussens et al.,
2000; Du et al., 2008; Fan and Malik, 2003; Mantovani et al.,Significance
Conceptually, our results introduce the idea that S1PR1-STAT3
arrival, which empowers myeloid cells to invade, proliferate an
a role ofmyeloid cells in regulating fibroblasts by producing fac
tion of premetastatic niches. Additionally, we demonstrate the a
metastatic niche formation in bone marrow-derived cells. Perh
therapeutic potential to target the S1PR1-STAT3 signaling axis
thereby preventing tumor metastasis.
642 Cancer Cell 21, 642–654, May 15, 2012 ª2012 Elsevier Inc.2008; Pollard, 2004; Shojaei et al., 2007), myeloid cells need to
proliferate and evade apoptosis in order to establish colonies
at future metastatic sites. However, mechanisms that enable
myeloid cells to colonize in the hostile environment at future
metastatic sites remain to be identified. In addition, the under-
lying molecular mechanism(s) that orchestrates tumor cells,
myeloid cells, resident fibroblasts, and other stromal cell types
to achieve outgrowths prior to tumor cell arrival at distant organs
remains unknown. A more complete body of knowledge on such
molecular mechanisms may facilitate translation of potentially
paradigm-shifting therapeutic strategies for the treatment ofsignaling axis is elevated in distant organs prior to tumor cell
d resist apoptosis at premetastatic sites. We further identify
tors similar to those of tumor cells, thereby facilitating forma-
bility of STAT3 in regulating numerous genes crucial for pre-
aps the most significant aspect of our current studies is the
to eliminate and/or reduce preformed premetastatic niches,
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detection of metastasis.
Persistently activated STAT3 in tumor cells acting as a crucial
oncogenic mediator and potent transcriptional factor has been
widely documented (Bollrath et al., 2009; Bromberg et al.,
1999; Catlett-Falcone et al., 1999; Chiarle et al., 2005; Fukuda
et al., 2011; Grivennikov et al., 2009; Lee et al., 2010; Lesina
et al., 2011; Yu et al., 2007, 2009). Recent studies have also
demonstrated persistent activation of STAT3 in myeloid cells
and T cells at primary tumor sites, promoting immunosuppres-
sion, tumor angiogenesis, tumor growth, andmetastasis (Biswas
and Mantovani, 2010; Kortylewski et al., 2005, 2009c; Kujawski
et al., 2008; Wang et al., 2009). While many cytokines, chemo-
kines, and growth factors can activate STAT3 in tumor cells
and in tumor-associated stromal cells (Biswas and Mantovani,
2010; Bollrath et al., 2009; Catlett-Falcone et al., 1999; Grivenni-
kov et al., 2009; Kortylewski et al., 2009c; Kujawski et al., 2008;
Lee et al., 2010; Lesina et al., 2011; Wang et al., 2009; Yu et al.,
2007), our recent studies showed a critical role of S1PR1 inmain-
taining persistent STAT3 activation in primary tumors, by regu-
lating both tumor cells and tumor-infiltrating myeloid cells (Lee
et al., 2010). S1PR1 and its ligand, S1P, play a fundamental
role in endothelial cells for regulating tumor angiogenesis, which
is also crucial for metastasis (Chae et al., 2004; Gao et al., 2008;
Holmgren et al., 1995; Spiegel and Milstien, 2003; Visentin et al.,
2006). Although the importance of tumor-infiltratingmyeloid cells
in facilitating tumor cell invasion and metastasis is well estab-
lished, the role of myeloid cells in forming a sanctuary for
tumor cells in distant organs prior to tumor cell arrival/
outgrowth has only begun to be appreciated (Erler et al., 2009;
Kaplan et al., 2005; Psaila and Lyden, 2009). Our current study
investigates whether STAT3 is persistently activated at future
metastatic sites prior to tumor cell arrival and whether S1PR1-
STAT3 signaling in both tumor cells and myeloid cells is critical
for tumor cell outgrowth/metastasis, and thus a potential thera-
peutic target.
RESULTS
S1PR1-STAT3-Induced Tumor Factors Activate
S1PR1-STAT3 at Distant Premetastatic Sites
To investigate whether increased STAT3 signaling in tumor cells
would induce production of factors that could prime distant pre-
metastatic sites, we generated tumor conditioned media (TCM)
from control or S1pr1 overexpressing (S1pr1high) mouse B16
melanoma and MB49 bladder tumor cells. The parental tumor
cells display relatively low Stat3 activation in cultured cells,
which was elevated by S1pr1 overexpression (Lee et al., 2010).
We examined several factors known to activate Stat3, and de-
tected elevated levels of both IL-6 and IL-10 in the TCM derived
from the S1pr1high tumor cells (Figure S1A available online). We
treated mice with TCMs from control and S1pr1high tumor cells
for 5 days prior to parental tumor cell challenge. Three days after
tumor challenge when there were no detectable metastases, we
observed extensive CD11b+ myeloid cell cluster formation in the
lung (Figure 1A). Importantly, we also observed widespread
Stat3 activation in lung-associated stromal cells by tumor-
secreted factors (Figures S1B and S1C). Further analyses of
CD11b+ myeloid cells indicated that changing Stat3 activity intumor cells altered the number of myeloid-derived suppressor
cells (Figure S1D).
We next performed experiments to ensure that in the absence
of tumor cell challenge, treatment with TCM derived from
S1pr1high tumor cells could activate Stat3 in future metastatic
sites and induce premetastatic niche formation in distant future
metastatic sites. Our results showed that treating mice with the
TCM from S1pr1high tumor cells for 5 days could induce strong
Stat3 activation and myeloid infiltration without tumor cell chal-
lenge (Figure 1B). Stat3 activity was detectable in myeloid cells
and also widespread in the lung (Figure 1B). Furthermore, treat-
ing mice with TCM generated from S1pr1high tumor cells, but not
TCM derived from control tumor cells, was able to induce S1pr1
expression and phosphorylated Stat3 (p-Stat3) in both lung
CD11b+ myeloid cells and metastatic nodules, which was
accompanied by extensive metastasis at days 9 and 14 post-
tumor cell challenge (Figure 1C). We also observed an increase
in total Stat3 protein level, which is likely caused by autoregula-
tion of p-Stat3.
Since resident fibroblasts at future metastatic sites play an
important role in premetastatic niche formation (Kaplan et al.,
2005; Orimo et al., 2005), and because we detected extensive
Stat3 activation at the future metastatic sites (Figures 1A and
1B), we tested whether S1pr1-Stat3-induced tumor factors
could activate fibroblasts to produce fibronectin, a factor
crucial for premetastatic niche formation (Erler et al., 2009; Ka-
plan et al., 2005; Psaila and Lyden, 2009). Treating mouse
embryonic fibroblasts (MEFs), as well as primary fibroblasts
derived from mouse lungs, with TCM prepared from S1pr1high
tumor cells, but not that from control tumor cells, induced fibro-
nectin expression and Stat3 activation (Figure 1D). Trypsin
treatment of TCM for S1pr1high tumor cells blocked fibronectin
and Stat3 activation in the fibroblasts. Heat treatment of the
same TCM also, to a lesser degree, reduced p-Stat3 level
(Figure S1E).
Myeloid Cell S1PR1-STAT3 Is Crucial for Premetastatic
Niche Formation
Since S1PR1-STAT3 signaling is activated at premetastatic
sites and in myeloid clusters, we assessed whether Stat3
activation intrinsic to myeloid cells is required for maintaining
S1pr1-Stat3 activity in the premetastatic sites and for formation
of premetastatic niches. We induced Stat3 ablation in the
myeloid compartment with poly(I:C) treatment using Mx1Cre-
Stat3loxp/loxp mice. Relative to the control Stat3loxp/loxp mice
with intact Stat3 alleles, ablating Stat3 in the myeloid compart-
ment of Mx1Cre-Stat3loxp/loxp mice effectively reduced Stat3
activity in the entire lung and eliminated formation of premeta-
static niches (Figure 2A), as well as lung metastasis (Figure 2B,
upper panel). In addition to CD11b+ cells, endothelial cells and
fibroblasts were among the p-Stat3-positive cells, which were
reduced by ablating Stat3 in the myeloid compartment (Fig-
ure 2B, lower panel).
In vivo ablating S1pr1 in myeloid cells using Mx1Cre-
S1pr1loxp/loxp mice reduced Stat3 activity and myeloid clusters
in the lung (Figure 2C). Additionally, increased S1pr1 expression
in tumor cells led to production of factors that elevated S1pr1
and p-Stat3 levels in the lungs, which required myeloid cell-
specific S1pr1 expression (Figure S2A). The reduction in S1pr1Cancer Cell 21, 642–654, May 15, 2012 ª2012 Elsevier Inc. 643
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Figure 1. S1PR1-STAT3-Induced Tumor Factors Activate STAT3 at Premetastatic Sites
(A) Left: Confocal microscopy images show phospho-Stat3 (p-Stat3, green) in myeloid cell clusters (CD11b, red) and other cells in premetastatic lung tissue
sections frommice treated with TCMs from control or S1pr1 overexpressing tumor cells for 5 days, followed by systemic tumor challenge for 3 days. Scale bars,
20 mm. Right, quantification of infiltrating CD11b+ cells shown on left (n = 10).
(B) Immunofluorescence (IF) staining measuring p-Stat3 and CD11b in lung sections from naive mice (upper panel) and mice treated with TCM from S1pr1high
MB49 tumor cells for 5 days without tumor challenge (lower panel). Left: representative confocal images from 4mice per group. Right, quantification of infiltrating
CD11b+ cells. Scale bars, 20 mm.
(C) Left panel, western blotting showing S1pr1, Stat3, and p-Stat3 in lung CD11b+ myeloid cells and metastatic nodules in mice 14 days post-tumor injection.
Right panel, representative lung metastasis and H&E staining (n = 6). Scale bars, 100 mm.
(D) Western blotting showing expression levels of fibronectin and p-Stat3 in MEFs (left) and primary lung-derived fibroblasts (right) exposed to indicated media.
Results represent means ± SEM. **p < 0.01, ***p < 0.001.
See also Figure S1.
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Figure 2. Ablating S1pr1 or Stat3 in Myeloid Cells Abrogates Tumor Factor-Induced Premetastatic Niches
(A) Representative immunofluorescence staining and confocal microscopy of p-Stat3 and CD11b+myeloid cells in lung tissues harvested frommice with Stat3+/+
and Stat3–/– myeloid compartment. Right, quantification of the images (n = 9). Scale bars, 20 mm.
(B) Upper left panel, enumeration of metastatic lung nodules in mice with Stat3+/+ and Stat3–/– myeloid compartment treated with indicated TCMs followed by
parental tumor cell challenge (n = 9). Upper right panel, H&E staining shows histology of lungs from representative mice in each group, arrows indicate lung
metastasis. Scale bars, 100 mm. Lower panel, flow cytometric analysis and western blotting measuring p-Stat3 in endothelial cells (CD31+aSMA) and fibroblasts
(CD31aSMA+) in premetastatic sites.
(C) Mice were treated with indicated TCMs, followed by systemic parental tumor cell challenge. Left upper panel, IHC staining evaluates p-Stat3 expression in
lung tissues from mice with S1pr1+/+ or S1pr1/ myeloid compartment. Scale bars, 20 mm. Left lower panel, CD11b+ myeloid cell clusters were analyzed by
confocal microscopy. Scale bars, 100 mm. Right panel, bar graph indicates number of lung nodules frommice with S1pr1+/+ and S1pr1/myeloid compartment
(n = 6).
Results represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S2.
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Stat3 Signaling and Myeloid Cell Colonizationexpression and Stat3 activity in the lungs of Mx1Cre-
S1pr1loxp/loxp mice was accompanied by drastically reduced
lung metastasis (Figure 2C, right). Collectively, these data
suggest that S1pr1-Stat3 signaling in myeloid cells contributes
to premetastatic niche formation, and extensive Stat3 activation
in the lung, as well as tumor metastasis. We further analyzed the
effects of S1pr1 and Stat3 ablation on subtypes of CD11b+ cells,
such as M1 and M2, as well as N1 and N2, derived from the lung
premetastatic sites (Figures S2B and S2C). Moreover, lack of
Stat3 inmyeloid cells did not significantly change the percentage
of myeloid cells in bone marrow and spleen (Figure S2D). T cell
subsets were affected by Stat3 ablation in myeloid compartment
at premetastatic niche sites (Figures S2E and S2F). Ablating
Stat3 in myeloid cells also increased T cell proliferation (Figures
S2G and S2H).
Targeting S1PR1 or STAT3 in Myeloid Cells Reduces
Preformed Metastatic Niches
For potential clinical translation of our results that S1PR1-STAT3
in myeloid cells is critical for premetastatic niche formation, we
assessed whether in vivo targeting of Stat3 or S1pr1 in myeloid
compartment by CpG-Stat3 siRNA and CpG-S1pr1 siRNA
would effectively reduce preformed metastatic niches at distant
organs and thereby prevent metastasis. CpG is a small oligonu-
cleotide with methylated CpG dinucleotides that activate Toll-
like receptor (TLR)-9, which is mainly expressed in the endoso-
mal compartment of myeloid and B cells (Kortylewski et al.,
2009b). CpG-siRNA can facilitate specific gene silencing in
these cells in vivo (Kortylewski et al., 2009b). We first induced
premetastatic niches using TCM from S1pr1high B16 tumor cells,
followed by parental tumor cell injection. The level of S1pr1
expression was elevated in lungs of mice treated with TCM rela-
tive to lungs from control naive mice (Figure S3A). After myeloid
cell cluster formation in the lung, mice were treated with CpG-
S1pr1 siRNA. We collected the lungs and analyzed CD11b+
myeloid cells by immunofluorescence staining 3 days after the
last CpG-S1pr1 siRNA treatment. In control CpG-Luciferase
siRNA-treated mice, we observed abundant myeloid cell infiltra-
tion near the distal alveoli (Figure 3A, left), which are the
common sites for cell infiltration and metastatic niche formation
(Kaplan et al., 2005). In the CpG-S1pr1 siRNA treatment group,
myeloid cell infiltration and cluster formation were drastically
reduced compared to those treated with control CpG-Luciferase
siRNA (Figure 3A). S1pr1 expression in the whole lung was
reduced in the CpG-S1pr1 siRNA-treated group relative to
controls (Figure 3B, left). The number of lung metastatic nodules
was also greatly reduced by treatment with CpG-S1pr1 siRNA
(Figure 3B, right). We also performed similar experiments with
CpG-Stat3 siRNA to test whether blocking Stat3 in myeloid cells
would reduce preformed premetastatic niches and tumor
metastasis. Directly targeting Stat3 in myeloid by CpG-Stat3
siRNA further reduced tumor factor-induced lung metastasis
(Figure 3C). The control CpG-Luciferase siRNA treatment also
led to somewhat a decrease in lung metastasis compared to
PBS treatment, which is likely due to the immune stimulatory
effect of CpG (Kortylewski et al., 2009b). We also used inducible
genetic ablation of Stat3 in myeloid cells to confirm that target-
ing Stat3 in myeloid cells can eliminate pre-existing metastatic
niches and metastasis (Figure S3B). CpG-Stat3 siRNA was646 Cancer Cell 21, 642–654, May 15, 2012 ª2012 Elsevier Inc.also able to eliminate premetastatic that were already formed
in lungs after mice were treated with the TCM derived from
S1pr1high tumor cells (Figure S3C). To assess whether the
maintenance of the premetastatic niche requires ongoing
production of tumor factors, we performed experiments in which
lung myeloid infiltrates were assessed at various time points
after treatments with tumor conditioned media was stopped.
Data generated from this set of experiments suggest that
ongoing production of tumor factors is crucial for the mainte-
nance of the myeloid cell infiltrates in the premetastatic niches
(Figure 3D).
STAT3 Signaling Enables Myeloid Cell Invasion
and Priming of Premetastatic Sites
Initiation of metastasis involves intravasation of tumor stromal
cells, including myeloid cells, from primary tumor sites (Fidler,
2003). We determined whether increasing STAT3 activity
intrinsic to myeloid cells could promote their intravasation
capacity from primary tumor. We visualized, by multiphoton
live imaging, interaction of myeloid cells with tumor endothelium,
as a result of increasing Stat3 activity by S1pr1high myeloid cells
(Figure 4A; Figures S4A and S4B). To further validate that Stat3
activity is crucial for myeloid cells to intravasate at primary
tumors, we performed time-lapsed two-photon imaging (Movies
S1, S2, S3, and S4), as well as trans-endothelial migration
assays with CD11b+ and CD11b+Gr1+ myeloid cells (Figure 4B).
Recent studies emphasize the importance of tumor-secreted
factors for premetastatic niche formation (Erler et al., 2009;
Hiratsuka et al., 2006; Kim et al., 2009). We next addressed
whether myeloid cells, through the S1PR1-STAT3 signaling
axis, could also produce factors to condition future metastatic
sites. We treated MEFs and primary lung-derived fibroblasts
with conditioned media from control and S1pr1high myeloid cells
and found that both p-Stat3 and fibronectin protein level were
higher in fibroblasts treated with conditioned medium from
S1pr1high myeloid cells compared to those treated with control
conditioned medium (Figure 4C). We also detected elevated
expression of IL-6, IL-10, and S1P by S1pr1high myeloid cells
(Figure S4C). In addition, S1pr1high myeloid cells mediated
increased metastasis (Figure S4D) and produced elevated Vegf
and Hif-1a mRNA and secreted VEGF levels (Figure 4D).
Expression of the receptor for fibronectin, integrin a4b1, by
VEGFR1+ myeloid cells has been demonstrated to be critical
for premetastatic niche formation (Kaplan et al., 2005). We there-
fore asked the question whether integrin a4b1 and fibronectin
are regulated by Stat3. Real-time PCR revealed that myeloid
cells express Fibronectin (also known as Fn1) in a Stat3-depen-
dent manner (Figure 5A). Tumor cell-produced lysyl oxidase
(LOX) has recently been shown to be critical for premetastatic
formation (Erler et al., 2009). Real-time PCR analysis indicated
that Stat3 could upregulate Lox expression in myeloid cells (Fig-
ure 5A). We identified STAT-binding sites in the promoter regions
of ITGA4 (encoding integrin a4), Fibronectin, and LOX using
Transfec. Moreover, chromatin immunoprecipitation (ChIP)
assays using chromatins prepared from bone marrow-derived
macrophages (BMDMs) exposed to S1pr1high TCM indicated
that Stat3 protein can directly bind to these sites, suggesting
that Itga4, Fibronectin, and Lox are Stat3-target genes, at least
in mouse cells (Figure 5B; Figure S5A).
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Figure 3. Targeting S1PR1 and STAT3 in Myeloid Cells Can Eliminate Preformed Metastatic Niches
(A) Immunofluorescence staining showing lung myeloid cell infiltrates in mice receiving indicated CpG-siRNA treatments. Left panel: representative images from
each group. The images in the lower panel showmagnification of upper row of images. Red, CD11b+myeloid cells; blue, Hoechst staining for nuclei. Right panel:
quantification of images on left (n = 8). Scale bars, 20 mm.
(B) Left panel, western blotting measuring effects of CpG-S1pr1 siRNA on S1pr1 protein expression levels in whole lungs. Right panel, lung metastasis was
enumerated after tumor challenge and CpG-S1pr1 siRNA treatment; shown are representative results from three experiments (n = 6).
(C) Left panel, lung metastatic colonies were enumerated frommice receiving indicated treatments (n = 5). Right panel, representative photos of lungs harvested
from mice treated with indicated CpG-siRNA conjugates.
(D) Lung-infiltrating CD11b+ cells were assessed by confocal microscopy. Mice were treated with S1pr1high TCM for 5 days. Upper panel, IF staining of CD11b+
cells in mouse lung tissues harvested at indicated time points after cessation of treatments. Lower left panel, IF staining of CD11b+ cells in a control mouse lung.
Scale bars, 50 mm. Lower right panel, quantification of lung infiltrating CD11b+ cells in upper panel (n = 4).
Results represent means ± SEM. *p < 0.05, ***p < 0.001.
See also Figure S3.
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Figure 4. STAT3 in Myeloid Cells Increases
Self Invasion and Tumor Metastasis
(A) Intravital two-photon live imaging of primary
tumors, visualizing myeloid cell interaction with
tumor endothelium. Green, CD11b+ myeloid cells
transducedwith either S1pr1 expressing retrovirus
or control retrovirus vector with eGFP tag; Red,
blood vessels labeled with rhodamine-dextran.
Scale bars, 100 mm.
(B) Trans-endothelial migration assay of Stat3+/+
and Stat3/ myeloid cells to migrate across
endothelial cells in response to S1pr1high TCM.
Migrated CD11b+ (left panel) and CD11b+Gr1+
(right panel) myeloid cells were further analyzed by
flow cytometry and normalized by input total cell
numbers; data represents one of three indepen-
dent experiments.
(C) Western blotting showing Fibronectin and
p-Stat3 proteins in MEFs (left) or primary lung-
derived fibroblasts (right) incubated with condi-
tioned media (CM) from myeloid cells with or
without S1pr1 overexpression.
(D) Left panel, real-time PCR analysis of whole
tumor mixture showing Hif-1a and Vegf
mRNA expression levels, which is normalized
by Gapdh expression (n = 8). Right panel, tumor
secreted VEGF levels were assessed by ELISA
using conditioned medium from whole tumors
(n = 10).
Results represent means ± SEM. *p < 0.05,
**p < 0.01.
See also Figure S4 and Movies S1, S2, S3,
and S4.
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regulated genes involved in invasion and matrix-remodeling,
processes critical for premetastatic niche formation (Yu et al.,
2009) in the BMDMs. Real-time PCR results confirmed that
tumor factors can induce expression of Cxcl2, Cxcl12, Cxcr4,
Mmp2, Cox-2 in BMDMs in a Stat3-dependent manner (Fig-
ure 5A). Furthermore, we showed that tumor factors from
S1pr1high tumor cells induced expression of Il6, Il1b, Cxcl2,
Cxcl12, and Mmp2 in lung-infiltrating myeloid cells, which is
also Stat3-dependent (Figure S5B).
To determine whether myeloid cell production of these
STAT3-dependent factors would impact their expression at
metastatic sites, we performed ChIP assay using lung tissues
collected from mice with Stat3+/+ and Stat3/ in myeloid
compartment, challenged with tumor cells. Without Stat3 in
the myeloid compartment, metastatic lungs exhibited lowered
levels of p-Stat3 (Figure 5C, right). The lung tissue ChIP assays648 Cancer Cell 21, 642–654, May 15, 2012 ª2012 Elsevier Inc.indicated that Stat3 binds to the
promoters of Lox, Mmp2, Mmp9, Itga4,
and Cxcl12 in the metastatic tissues (Fig-
ure 5C, left). Taken together, we show
that through STAT3, whose persistent
activation is contributed by S1PR1 in
the tumor microenvironment, myeloid
cells can express multiple key factors
for various aspects of premetastatic
niche formation, allowing them to primethe microenvironment at future metastatic sites for their own
settlement.
S1PR1-STAT3 Signaling Enables Myeloid Cells to
Colonize at Premetastatic Sites
While invasion potential is critical for myeloid cells to colonize/
form premetastatic niches at distal organs, myeloid cells must
proliferate and evade apoptosis. We therefore assessedwhether
STAT3 signaling could upregulate expression of prosurvival and
proproliferative genes in myeloid cells. Real-time PCR analysis
indicated that expression of several prosurvival and proprolifer-
ative genes in BMDMs in response to tumor factors was Stat3
dependent (Figure 5A). Expression of the antiproliferative and
proapoptotic gene, p53 (Niu et al., 2005), was inhibited by
Stat3 in myeloid cells when exposed to the tumor milieu (Fig-
ure 5A). To test whether S1PR1-STAT3 signaling in myeloid cells
leads to increased proliferation in future metastatic sites, we
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Figure 5. STAT3 Signaling Facilitates Myeloid Cell Colonization
(A) Real-time PCR showing Stat3-dependent expression of indicated genes in Stat3+/+ and Stat3–/– bone marrow-derived macrophages (BMDMs) exposed to
TCM (n = 3).
(B) ChIP using BMDMs showing Itga4, Fibronectin and Lox are direct Stat3 target genes. DNA electrophoresis shows DNA fragments within the indicated
promoters detected by specific primers. PIS (preimmune serum) antibody was used for immunoprecipitation as a negative control (n = 10).
(C) In vivo ChIP assay of lung tissues collected frommice with Stat3+/+ or Stat3/myeloid compartment treated with TCM prior to tumor cell challenge. All ChIP
data were quantified by real-time PCR in comparison with input DNA, and normalized with Stat3/ samples set as one. ChIP assay performed in triplicate.
(D) Left panels: double immunofluorescence staining with proliferation marker Ki-67 and myeloid cells marker CD11b, of lung tissue sections prepared from
mice with S1pr1+/+ or S1pr1/ myeloid compartment and treated with indicated TCMs. Inset shows magnification at specified region. Right panels: immu-
nofluorescence staining for detection of Survivin and CD11b in the lungs of indicated mice. Scale bars, 50 mm.
Results represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S5.
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Stat3 Signaling and Myeloid Cell Colonizationassessed proliferation index (Ki-67) in the lungs of mice following
systemic treatment with S1pr1high TCM and found that tumor-
derived soluble factors could promote proliferation of cells in
premetastatic niches but it depended on S1pr1-Stat3 in themyeloid compartment (Figure 5D, left panels). Notably, the
increase in cell proliferation in the premetastatic sites was not
restricted to myeloid cells, which was consistent with Stat3 acti-
vation in various cells in addition to themyeloid clusters (Figure 1;Cancer Cell 21, 642–654, May 15, 2012 ª2012 Elsevier Inc. 649
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Stat3 Signaling and Myeloid Cell ColonizationFigure S1).We further showed that factors fromS1pr1high tumors
cells induced Stat3-dependent expression of prosurvival/
proliferation genes in lung-infiltrating myeloid cells (Figure S5B).
In order to colonize distant sites, myeloid cells must also be
able to evade apoptosis in the hostile environment of distant
organs. We therefore determined anti-apoptotic gene Survivin
expression in lung tissue sections adjacent to those used for
proliferation analysis. Our results indicated a significant increase
in the number of Survivin-positive cells in lungs harvested from
mice treated with S1pr1high TCM (Figure 5D, right panels).
Ablating S1pr1 in the myeloid compartment abrogated Survivin
induction by TCM (Figure 5D, right panels). Consistent with
this, we observed Stat3-dependent Survivin expression in
BMDMs exposed to TCM (Figure 5A).
STAT3 Signaling and Effects in Premetastatic Human
Patient Tissues
To extend our findings to human cancers, we analyzed S1PR1
expression and STAT3 activity in uninvolved (tumor cell-free)
lymph nodes from high-risk prostate cancer patients and mela-
noma patients, and from individual without malignancy. We
were able to detect strong STAT3 activation in the primary tumor
sites (data not shown), and heavy CD68+ myeloid infiltrates in 40
out of 50 uninvolved lymph nodes from the prostate cancer
patients, and four out of five uninvolved lymph nodes from the
melanoma patients (Figure 6A). CD68+ areas in the lymph nodes
also displayed elevated S1PR1 expression and p-STAT3 (Fig-
ure 6A). Immunohistochemical staining with another myeloid
cells marker, CD33, showed a similar staining pattern as CD68
(Figure S6A). As in mouse premetastatic sites, cells other than
myeloid cells including those in the endothelium, also showed
increased S1PR1 expression and p-STAT3 levels (Figure S6B).
Similar to a prior report (Kaplan et al., 2005), we did not observe
heavy CD68+ myeloid infiltrates in the lymph node sections
from individual without cancer (Figure 6A). Only weak S1PR1
and p-STAT3 was detected inside normal control lymph nodes
(Figure 6A). We further tested SURVIVIN expression in lymph
nodes from individuals with prostate cancer and without cancer
(Figure 6B, left panel). Quantification of relative expression levels
of CD68 and SURVIVIN in the patient lymph nodes versus normal
lymph node is also shown (Figure S6C). Expression of BCL2L1 in
uninvolved lymph nodes from melanoma patients was associ-
ated with elevated p-STAT3 (Figure 6B, right panel).
DISCUSSION
Recent studies suggest a paradigm-shifting concept that non-
neoplastic cell populations, such as myeloid cells, are crucial
in providing tumor cells a conducive microenvironment to
engraft and colonize in distant organs (Erler et al., 2009; Hirat-
suka et al., 2006; Kaplan et al., 2005; Kim et al., 2009; Kowanetz
et al., 2010; Psaila and Lyden, 2009). This current study intro-
duces the concept that persistent activation of STAT3 occurs
in distant organs before tumor cell arrival. Stat3 orS1pr1 ablation
in myeloid cells also abrogated Stat3 activity in the entire future
metastatic site, further suggesting an important role of myeloid
cells in establishing premetastatic niches. While induced abla-
tion in the Mx-Cre mice also, to a lesser degree, affects other
types of cells in addition to hematopoietic cells, results from650 Cancer Cell 21, 642–654, May 15, 2012 ª2012 Elsevier Inc.CpG-siRNA treatments, which selectively targeting TLR-9+
cells (Kortylewski et al., 2009a, 2009b), support the notion that
targeting STAT3/S1PR1 signaling in immune cells can reduce
STAT3 activity and myeloid cell infiltrates in future metastatic
sites. Consistent with previous studies (Erler et al., 2009; Kaplan
et al., 2005; Kim et al., 2009), we show that tumor cell-produced
factors, whose upregulation is contributed by S1PR1-STAT3
signaling, are critical in initiating premetastatic niche formation.
Our results further indicate that the maintenance of the niche
requires ongoing production of tumor factors, suggesting if
the tumors are removed timely and completely there would not
be premetastatic niches for therapeutic intervention. However,
many patients cannot have their tumors removed timely and/or
completely, causing relapses. Therefore, targeting premeta-
static niches to prevent/reduce metastasis in these patients
can be highly desirable. We show that S1PR1-STAT3
signaling-induced tumor factors can prime/activate fibroblasts,
which are crucial for forming premetastatic niches at distant
organs. These results, taken together, suggest a critical role of
S1PR1-STAT3 not only in tumor cells, but also in myeloid cells,
and likely in other types of stromal cells including fibroblasts
and endothelial cells, in orchestrating premetastatic niche
formation.
The focus on initiating distant organ metastasis through
myeloid cells has been on tumor cell-produced factors (Erler
et al., 2009; Kaplan et al., 2005; Kim et al., 2009). Our data
suggest that once STAT3 is persistently activated, myeloid cells
produce similar factors as tumor cells, including IL-6 and IL-10,
capable of activating fibroblasts and upregulating key mole-
cules, such as fibronectin (Kaplan et al., 2005; Kenny et al.,
2008), for premetastatic niche formation. Being able to express
integrins and produce chemokines, growth factors, angiogenic
factors, and inflammatory mediators in response to tumor
factors, is viewed as the primary function of myeloid cells in
forming premetastatic niches (Psaila and Lyden, 2009). While
these factors/molecules clearly play an important role in preme-
tastatic niche formation, to achieve outgrowth in the hostile
environment of distant organs, nonneoplastic cells must sustain
proliferation and resist apoptosis. Our results suggest that
persistent STAT3 signaling in myeloid cells can increase their
proliferation and survival, as well as that of other stromal
cells at future metastatic sites. It was previously reported that
ablating Stat3 in myeloid cells could enhance the development
and progression of colorectal cancer, presumably through inhi-
bition of IL-10 signaling (Deng et al., 2010). In other colorectal
cancer models, however, blocking Stat3 was associated with
a decrease in tumor development/progression due to inhibition
of Th17 (Wu et al., 2009). These results suggest the complexity
of immunoregulation in colon cancer, which is greatly impacted
by STAT3. At the same time, in many cancers, the role of STAT3
in promoting cancer development and progression has been
demonstrated (Yu et al., 2009).
Prior publications suggest that myeloid cells migrate into
distant organs from bone marrow without necessarily passing
through the primary tumor site (Erler et al., 2009). Our data
indicate that S1PR1-STAT3 upregulation in myeloid cells at
primary tumor sites can promote their intravasation, which might
facilitate their accumulation in future metastatic sites. Activation
of Toll-like receptors, specifically TLR2, on myeloid cells by
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Figure 6. STAT3 Is Activated in Myeloid Clusters in Human Premetastatic Sites
(A) IHC staining of p-STAT3, S1PR1, and CD68 from uninvolved lymph nodes from prostate and melanoma cancer patients with high metastatic potential (upper
and middle panels, respectively) or from a control lymph node from an individual without cancer (lower panels).
(B) Immunofluorescence staining from adjacent sections of the same tissues as in (A). Left panel, green, SURVIVIN; red, CD68 of humanmyeloid cells; blue, nuclei
stained with Hoechst. Data on prostate cancer patient lymph nodes are representative of 15 independent patient samples. Right panel, uninvolved lymph nodes
from melanoma patients are stained for p-STAT3 (green) and BCL2L1 (red). Nuclei counter stained with Hoechst (blue).
Data are representative of samples from five melanoma patients. Scale bars, 50 mm.
See also Figure S6.
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Stat3 Signaling and Myeloid Cell Colonizationtumor-produced factors has been shown to create an inflamma-
tory milieu that mediates distant-site metastasis (Kim et al.,
2009). Because STAT3 can be activated by many inflammatory
stimuli through various receptors including Toll-like receptors,
and by smoking, carcinogen, radiation, andUV exposure, amongother external insults (Arredondo et al., 2006; Aziz et al., 2007;
Biswas and Mantovani, 2010; Bronte-Tinkew et al., 2009; Chan
et al., 2004; Psaila and Lyden, 2009; Wels et al., 2008; Yu et al.,
2009), our findings support the concept that environmental
conditions may contribute to cancer metastasis.Cancer Cell 21, 642–654, May 15, 2012 ª2012 Elsevier Inc. 651
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Stat3 Signaling and Myeloid Cell ColonizationMetastasis remains the final frontier for cancer therapy (Klein,
2009; Psaila and Lyden, 2009; Steeg, 2006; Wels et al., 2008).
Being able to prevent metastasis by eliminating premetastatic
niches is an attractive approach for effective cancer treatment.
Our study suggests that the S1PR1-STAT3 axis is operative in
not only tumor cells, but also myeloid cells, and likely other types
of stromal cells crucially involved in forming premetastatic
niches. Our data further expand the STAT3-regulated down-
stream genes involved in premetastatic niche formation. These
studies demonstrate that S1PR1-STAT3 is an effective target
to disable both tumor cells and ‘‘nonneoplastic’’ cells from
creating an environment that is crucial for malignant distant
outgrowth.
EXPERIMENTAL PROCEDURES
Tumor and Myeloid Conditioned Media Preparation
Tumor cells (B16, MB49) were transduced with MSCV retrovirus with or
without S1pr1. Control and S1pr1 overexpressing tumor cell lines were incu-
bated in serum-free medium for 24 hr and TCM was collected and filtered
through 0.22 mm SFCA membrane (Corning, Inc.). To obtain myeloid cell
conditioned media, total splenocytes were harvested and transduced with
S1pr1-expressing GFP-tagged retrovirus. GFP+CD11b+ myeloid cells were
FACS sorted after a 24 hr infection, and supernatant was collected 24 hr after
culture in RPMI medium supplied with 10% FBS. The supernatants were
centrifuged at 3,000 rpm for 5 min.
In Vivo Experiments
Mouse care and experimental procedures were performed in accordance with
established institutional guidance and approved protocols from Institutional
Animal Care and Use Committee at Beckman Research Institute of City of
Hope National Medical Center. We obtained Mx1-Cre mice from Jackson
Laboratory and Stat3loxp/loxp mice from Drs. Shizuo Akira and Kiyoshi Takeda
(Osaka University). Stat3/ ablation in hematopoietic cells was accomplished
as previously described (Kortylewski et al., 2005). S1pr1loxp/loxp mice
(generous gift from Dr. Richard Proia) were crossed with Mx1-Cre mice to
generate S1pr1 deletion in hematopoietic cells as previously described (Lee
et al., 2010).
For TCM treatments, mice were treated by intraperitoneal injection of TCM
(300 ml) followed by parental tumor cell tail vein injection (1 3 105/mouse).
Lungs were perfused using HBSS, harvested and immediately embedded in
OCT or fixed with formalin.
For tumor cell/myeloid cell co-administration, GFP+CD11b+ myeloid cells,
transduced and sorted as described above, were mixed with either MB49 or
B16 tumor cells (1:10 ratio), and subsequently injected into mice either subcu-
taneously or through tail vein injection.
CpG conjugated siRNA was synthesized as previously described (Kortylew-
ski et al., 2009b). The sequences of CpG-Luc siRNA and CpG-Stat3 siRNA
conjugate molecules were reported elsewhere (Kortylewski et al., 2009b).
C57BL/6 mice were treated with TCM for 5 consecutive days, followed by
i.v. parental tumor cell challenge. Mice were first treated (i.v.) with CpG-siRNA
conjugates (0.78 nmol/mice) at day 7 post-tumor challenge, followed by every
other day treatment for 2 weeks. Lungs were perfused, harvested, and
embedded in OCT for further analysis.
Immunohistochemistry and Immunofluorescent Staining
and Analyses
Paraffin-embedded sections were deparaffinized, followed by staining with
antibodies against pY705-Stat3 (Cell Signaling Technology), S1PR1 (Santa
Cruz Biotechnology Inc.) or CD68 (AbD Serotec) and examined under Olympus
AX70 automated upright microscope. Frozen or deparaffinized sections were
stained with pY705-Stat3 (Santa Cruz Biotechnology Inc.), CD11b (BD
PharMingen), Ki-67 (Abcam), and Survivin (Novus Biologicals) antibodies.
For fluorescence detection, secondary antibodies were used (Alexa Fluor
488 and Alexa Fluor 546, Invitrogen) and counterstained with Hoechst 33432
(Invitrogen) for nuclei. Slides were mounted and examined using the Zeiss652 Cancer Cell 21, 642–654, May 15, 2012 ª2012 Elsevier Inc.cLSM510Meta inverted confocal microscope. Image-Pro Plus (MediaCyber-
netics) software was used to count the number of stained cells as indicated
in the figure legends for quantification purpose.
Intravital Two-Photon Imaging, Time-Lapse 3D Imaging, and
Analysis
After injection of tumor cells mixed with myeloid cells (GFP-tagged) for 9 days,
mice were retroorbitally injected with dextran-rhodamine (Invitrogen) and were
anesthetized 30 min later. Live imaging was performed using Prairie Ultima
microscope (Prairie Technologies, Madison, WI) as previously described (Kor-
tylewski et al., 2009b). Both green and red channels were excited at 860 nm,
with emission detected simultaneously between 500 and 550 nm (green/
GFP) and between 570 and 620 nm (red/Dextran). Multidimensional images
were created as previously reported (Wei et al., 2005), Z-stack images were
acquired (20x/1.0W objective by Olympus, 1024 3 1024 = 0.464 mm/pixel)
every 5 min for 13 time points to create a 4D data set (x, y, and z axes with
time and different emission wavelengths). Fourteen Z-sections were collected
at 3 mm intervals for a total of 42 mm. Z-stacks images were first assembled in
Image Pro Plus software version 6.3 (Media Cybernetics), and then 3D data
sets were generated using Amira software version 5.3.3 (Visage Imaging) using
Volren projections. Time-lapse sequences were created using Amira Demo
Maker and Movie Maker. Movies were saved in the MPG format with 200
frames at a rate of 24 fps.
Trans-Endothelial Migration Assay
Mouse prostate endothelial cells were seeded in 24-well transwell inserts
(Corning Costar Corp.) with polycarbonate membranes (8.0 mm pore). For
trans-endothelial cell migration, myeloid cells were stained with CD11b and
Gr1 antibodies and re-suspended in leukocyte migration buffer containing
RPMI 1640 medium with 0.25% BSA (fatty acid free, Sigma), and added to
the upper chamber at 1 3 105/well. Cells were allowed to migrate toward
TCM in lower chamber for 1 hr. The numbers of migrated cells into lower
chamber were enumerated for different myeloid subpopulations by flow cy-
tometry at a fixed flow rate for 1 min on Accuri C6 flow cytometer. The
percentage of migrated cells was normalized by the total numbers of input
cells for each sample.
Chromatin Immunoprecipitation Assay
ChIP assays for cells and tissues were performed based on the protocol
from Millipore-Upstate Biotechnology. Rabbit anti-Stat3 (C-20, Santa Cruz
Biotechnology, Inc.) was used for immunoprecipitation. Potential STAT-
binding sites on mouse Lox, Fibronectin, Vla-4, Mmp2 and Mmp9 were
analyzed by Transfec software. The potential Stat binding sites are: Lox (50-
TTCCCATAA-30, 405 bp); Fibronectin (50-TTCCCACAA-30, 574 bp); Itga4
(50-TTCCCCCAA-30,229 bp);Mmp2 (50-TTCCTGGAA-30,1,667 bp);Mmp9
(50-TTCCCCAA-30, 579 bp). ChIP primers were designed to flank these
sites: for Lox, 50-CGTAGCAAGCTTTGTTCCCT-30, 50-GGGAGGTTGTGACTA
AGGCTTATGCT-30; Fibronectin, 50-AAACCGAGGTCTGAGCCTACCTAA-30,
50- AATTGGTGGCTGTGGTGGTGTTTG-30; Itga4, 50-CCCAAATTATTGGCC
ACTGGGACT-30, 50- ACCTAGGTTGCATGGACTCACA-30; Mmp2, 50-ATTG
GCAGGCCCATTTGGGTTGAT-30, 50-TCAGGGATTCACGGTTGTCACCTT-30,
Mmp9, 50-ATAGGGACAAAGGCTTGAGCGACA-30, 50- AGCAGGCTCTTTGA
GGCAGGATTT-30. Cxcl12 primer was used according to previous publication
(Stat3 biding site 50-TTCCCGGGAA-30, 527 bp) (Olive et al., 2008), 50-
ACCTGTTTGGTCTCTTTGCTCGGT-30, 50-CTGTCAAAGGCACAAGCCGTGA
AA-30. The relative amount of precipitated DNAs were quantified by real-
time PCR and normalized by input DNA.
Patient and Normal Lymph Node Specimens
Prostate cancer patient specimens were obtained through a City of Hope
Institutional Review Board approved protocol (COH IRB 09213) with consent
from patients. Briefly, 50 high-risk prostate cancer patients (defined by stan-
dard D’Amico criteria, i.e., baseline PSA >20 ng/m, Gleason grade 8–10, or
stage T3a-T4 disease), who were treated with prostatectomy, were selected.
Paraffin-embedded tissue from benign pelvic lymph nodes were obtained and
prepared as 4 mm sections on unstained slides for subsequent analyses.
Lymph node sections from melanoma were prepared for immunohistochem-
istry (IHC) analysis as previously described (de Maat et al., 2007), and were
Cancer Cell
Stat3 Signaling and Myeloid Cell Colonizationprovided by John Wayne Cancer Institute, with approval fromWestern Institu-
tional Review Board and with patient consent. Lymph node tissue sections
from individuals without cancer were purchased from Abcam. Tissue sections
were stained and examined as described above. Paraffin-embedded tissue
slides were stained with H&E and examined/diagnosed by a licensed
pathologist.
Statistics
Data are presented as means ± SEM. Statistical comparisons between groups
were performed using unpaired Student’s t tests to calculate the two-tailed
p value: *p < 0.05, **p < 0.01, ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, Supplemental Experimental
Procedures, and four movies and can be found with this article online at
doi:10.1016/j.ccr.2012.03.039.
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